US6066A
(en)
|
|
1849-01-30 |
|
Improvement in the manufacture of india-rubber |
US336A
(en)
|
|
1837-07-31 |
|
Improved process for removing wool and hair from skins |
US3383281A
(en)
|
1961-09-22 |
1968-05-14 |
Merck & Co Inc |
Method for binding bile acids in vivo
|
US3308020A
(en)
|
1961-09-22 |
1967-03-07 |
Merck & Co Inc |
Compositions and method for binding bile acids in vivo including hypocholesteremics
|
GB1348642A
(en)
|
1970-10-15 |
1974-03-20 |
Howard A N |
Hypocholesterolaemic compositions
|
US3769399A
(en)
|
1971-03-05 |
1973-10-30 |
L Hagerman |
Intestinal bile acid binding process and compositions
|
US3974272A
(en)
|
1972-09-01 |
1976-08-10 |
Merck & Co., Inc. |
Palatable cholestyramine coacervate compositions
|
US4252790A
(en)
|
1974-10-23 |
1981-02-24 |
Interx Research Corporation |
Method for treating gastric ulcer-prone patients
|
GB1566609A
(en)
|
1977-03-10 |
1980-05-08 |
Reckitt & Colmann Prod Ltd |
Pharmaceutical compositions containing cholestyramine and alginic acid
|
IT1106718B
(it)
|
1978-12-21 |
1985-11-18 |
Alfa Farmaceutici Spa |
Composizioni a base di resine anioniche salificate farmacologicamente attive
|
US4647459A
(en)
|
1983-07-20 |
1987-03-03 |
Warner-Lambert Company |
Confectionery compositions containing magnesium trisilicate adsorbates
|
US4771072A
(en)
|
1985-01-10 |
1988-09-13 |
Tanabe Seiyaku Co., Ltd. |
Alkoxynaphthalene derivatives
|
US4747881A
(en)
|
1985-02-05 |
1988-05-31 |
Warner-Lambert Company |
Ingestible aggregate and delivery system prepared therefrom
|
JPS6310746A
(ja)
|
1986-07-01 |
1988-01-18 |
Tanabe Seiyaku Co Ltd |
ナフタレン誘導体
|
US4895723A
(en)
|
1986-09-08 |
1990-01-23 |
Amer And Company |
Cholestyramine compositions and method for preparation thereof
|
US4814354A
(en)
|
1986-09-26 |
1989-03-21 |
Warner-Lambert Company |
Lipid regulating agents
|
US4874744A
(en)
|
1989-03-13 |
1989-10-17 |
University Of Cincinnati |
Method of using melanocyte stimulating hormone as dermatis treatment
|
US5275823A
(en)
|
1989-04-27 |
1994-01-04 |
Smith Kline & French Laboratories Ltd. |
Pharmaceutical compositions
|
DE3930696A1
(de)
|
1989-09-14 |
1991-03-28 |
Hoechst Ag |
Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
|
DK0489423T3
(da)
|
1990-12-06 |
1997-04-14 |
Hoechst Ag |
Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelsen af disse forbindelser som lægemidler
|
JP2839805B2
(ja)
|
1991-10-17 |
1998-12-16 |
塩野義製薬株式会社 |
リグナン類縁体及びその製造方法ならびに抗高脂血症剤
|
FI108451B
(fi)
|
1991-12-20 |
2002-01-31 |
Hoechst Ag |
Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi
|
GB9203347D0
(en)
|
1992-02-17 |
1992-04-01 |
Wellcome Found |
Hypolipidaemic compounds
|
EP0573848B1
(de)
|
1992-06-12 |
1997-12-03 |
Hoechst Aktiengesellschaft |
Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel
|
ZA941003B
(en)
|
1993-02-15 |
1995-08-14 |
Wellcome Found |
Hypolipidaemic compounds
|
IL108634A0
(en)
|
1993-02-15 |
1994-05-30 |
Wellcome Found |
Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
|
CN1046937C
(zh)
|
1993-04-16 |
1999-12-01 |
盐野义制药株式会社 |
木酚素系化合物的制备方法
|
DE4314583A1
(de)
|
1993-04-29 |
1994-11-03 |
Astra Chem Gmbh |
Colestyramin enthaltende Zusammensetzung und Verfahren zu deren Herstellung
|
TW289020B
(pt)
|
1993-05-08 |
1996-10-21 |
Hoechst Sktiengesellschaft |
|
TW289021B
(pt)
|
1993-05-08 |
1996-10-21 |
Hoechst Ag |
|
EP0624593A3
(de)
|
1993-05-08 |
1995-06-07 |
Hoechst Ag |
Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
|
ZA956647B
(en)
|
1994-08-10 |
1997-02-10 |
Wellcome Found |
Hypolipidaemic compounds.
|
EP0781278B1
(en)
|
1994-09-13 |
2001-03-14 |
Monsanto Company |
Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US5994391A
(en)
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6107494A
(en)
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
GB9423172D0
(en)
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
DE04010088T1
(de)
|
1996-03-11 |
2005-07-14 |
G.D. Searle Llc |
Neue Benzothiepine mit pharmazeutischer Wirkung.
|
WO1998007749A1
(en)
|
1996-08-23 |
1998-02-26 |
Human Genome Sciences, Inc. |
Novel human growth factors
|
JPH1072371A
(ja)
|
1996-08-28 |
1998-03-17 |
Sankyo Co Ltd |
回腸型胆汁酸トランスポーター阻害剤
|
GB9704208D0
(en)
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
NZ337830A
(en)
|
1997-03-11 |
2001-07-27 |
G |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
PT864582E
(pt)
|
1997-03-14 |
2003-10-31 |
Aventis Pharma Gmbh |
1,4-benzotiazepina-1,1-dioxidos hipolipidemicos
|
EP0869121B1
(de)
|
1997-04-04 |
2004-06-09 |
Aventis Pharma Deutschland GmbH |
Hypolipidämische Propanolaminderivate
|
DE19845402B4
(de)
|
1998-10-02 |
2005-04-07 |
Aventis Pharma Deutschland Gmbh |
Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
AU7552198A
(en)
|
1997-06-11 |
1998-12-30 |
Sankyo Company Limited |
Benzylamine derivatives
|
US6066336A
(en)
|
1997-09-29 |
2000-05-23 |
Bristol-Myers Squibb Company |
Cholesterol-lowering tablets
|
ES2195428T3
(es)
|
1997-12-19 |
2003-12-01 |
Searle & Co |
Metodo para preparar oxidos de tetrahidrobenzotiepina enriquecidos enantiometricamente.
|
GB9800428D0
(en)
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
DE19825804C2
(de)
|
1998-06-10 |
2000-08-24 |
Aventis Pharma Gmbh |
1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
|
DE19845403B4
(de)
|
1998-10-02 |
2005-02-10 |
Aventis Pharma Deutschland Gmbh |
Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE19845405C2
(de)
|
1998-10-02 |
2000-07-13 |
Aventis Pharma Gmbh |
Arylsubstituierte Propanolaminderivate und deren Verwendung
|
DE19845406C2
(de)
|
1998-10-02 |
2001-10-18 |
Aventis Pharma Gmbh |
Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
AU1684400A
(en)
|
1998-12-11 |
2000-07-03 |
Sankyo Company Limited |
Substituted benzylamines
|
CN1342090A
(zh)
|
1998-12-23 |
2002-03-27 |
G·D·瑟尔有限公司 |
适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
|
JP2002533414A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール エルエルシー |
心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
|
DE69911058T2
(de)
|
1998-12-23 |
2004-06-03 |
G.D. Searle Llc, Chicago |
Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
|
PL348508A1
(en)
|
1998-12-23 |
2002-05-20 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
EP1155007A2
(en)
|
1999-02-12 |
2001-11-21 |
G.D. Searle LLC |
1,2-benzothiazepines for the treatment of hyperlipidemic diseases
|
DE19916108C1
(de)
|
1999-04-09 |
2001-01-11 |
Aventis Pharma Gmbh |
Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
|
SE9901387D0
(sv)
|
1999-04-19 |
1999-04-19 |
Astra Ab |
New pharmaceutical foromaulations
|
CZ290178B6
(cs)
|
1999-07-22 |
2002-06-12 |
Sankyo Company Limited |
Deriváty cyklobutenu
|
ATE363074T1
(de)
|
1999-09-14 |
2007-06-15 |
Xenoport Inc |
Substrate und screeningverfahren für transportproteine
|
AU1302301A
(en)
|
1999-11-08 |
2001-06-06 |
Sankyo Company Limited |
Nitrogenous heterocycle derivatives
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
WO2001068096A2
(en)
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
EP1286984A2
(en)
|
2000-03-10 |
2003-03-05 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
US20020183307A1
(en)
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
IL156550A0
(en)
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
SK9502003A3
(en)
|
2001-01-26 |
2003-12-02 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
DE60220522T2
(de)
|
2001-07-19 |
2007-09-27 |
Pharmacia Corp. |
Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
|
NZ531293A
(en)
|
2001-08-22 |
2005-08-26 |
Aventis Pharma Gmbh |
Pharamceuticals containing 1,4-benzothiepine-1,1-dioxide derivatives and another active substances such as ezetimibe, pamaqueside or tiqueside for treating lipid metabolism and atherosclerotic disorders
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
WO2003022286A1
(en)
|
2001-09-08 |
2003-03-20 |
Astrazeneca Ab |
Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
|
WO2003022861A1
(en)
|
2001-09-13 |
2003-03-20 |
Bristol-Myers Squibb Company |
Process for the preparation of rebeccamycin and analogs thereof
|
JP2005504091A
(ja)
|
2001-09-21 |
2005-02-10 |
シェーリング コーポレイション |
ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
|
EP1448546A4
(en)
|
2001-11-02 |
2005-02-02 |
Searle Llc |
MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF TRANSPORT OF ACIDICALLY DEPENDENT SODIUM ACILIC (ASBT) BILIARY ACIDS AND TAUROCHOLATE RECOVERY
|
JP2005521653A
(ja)
|
2002-01-17 |
2005-07-21 |
ファルマシア コーポレイション |
先端ナトリウム同時依存性胆汁酸輸送(asbt)およびタウロコール酸塩取込みの阻害剤としての新規アルキル/アリールヒドロキシまたはケトチエピン化合物
|
US20040014806A1
(en)
|
2002-03-08 |
2004-01-22 |
Pharmacia Corporation |
Methods and compositions for lowering levels of blood lipids
|
GB0215579D0
(en)
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
US7312208B2
(en)
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
MXPA05004811A
(es)
|
2002-11-06 |
2005-07-22 |
Schering Corp |
Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
|
US20050031651A1
(en)
|
2002-12-24 |
2005-02-10 |
Francine Gervais |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
CN1756755A
(zh)
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
US7208486B2
(en)
|
2003-03-07 |
2007-04-24 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
WO2005027894A1
(en)
|
2003-09-19 |
2005-03-31 |
Pfizer Health Ab |
Enhanced method of treatment of growth disorders
|
CA2544309A1
(en)
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
EP1564554A1
(en)
|
2004-02-12 |
2005-08-17 |
Pepscan Systems B.V. |
Method for the detection of early B cell populations in vaccine development
|
DE102004016845A1
(de)
|
2004-04-07 |
2005-10-27 |
Bayer Healthcare Ag |
Phenylthioessigsäure-Derivate und ihre Verwendung
|
WO2006017257A2
(en)
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Azetidinone derivatives
|
DE102004046623A1
(de)
|
2004-09-25 |
2006-03-30 |
Bayer Healthcare Ag |
Neue Pyrimidin-Derivate und ihre Verwendung
|
JP2008514718A
(ja)
|
2004-09-29 |
2008-05-08 |
シェーリング コーポレイション |
置換アゼチドノンおよびcb1アンタゴニストの組み合わせ
|
JPWO2006041150A1
(ja)
|
2004-10-15 |
2008-05-22 |
田辺三菱製薬株式会社 |
糖尿病の予防および/または治療薬
|
CN102633730A
(zh)
|
2004-12-03 |
2012-08-15 |
先灵公司 |
作为cb1拮抗剂的取代哌嗪
|
DE102005027150A1
(de)
|
2005-03-12 |
2006-09-28 |
Bayer Healthcare Ag |
Pyrimidincarbonsäure-Derivate und ihre Verwendung
|
US8207133B1
(en)
|
2005-04-04 |
2012-06-26 |
Julius-Maximilians-Universitat Wurzburg |
Peptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1
|
CA2603452A1
(en)
|
2005-04-04 |
2006-10-12 |
Julius-Maximillians-Universitat Wurzburg |
Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
|
US20080194494A1
(en)
|
2005-04-26 |
2008-08-14 |
Microbia, Inc. |
4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
|
DE102005020229A1
(de)
|
2005-04-30 |
2006-11-09 |
Bayer Healthcare Ag |
Verwendung von Indolin-Phenylsulfonamid-Derivaten
|
US20090131395A1
(en)
|
2005-05-05 |
2009-05-21 |
Microbia, Inc. |
Biphenylazetidinone cholesterol absorption inhibitors
|
EP1879860A2
(en)
|
2005-05-10 |
2008-01-23 |
Microbia Inc. |
1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
|
EP1885694A2
(en)
|
2005-05-13 |
2008-02-13 |
Microbia, Inc. |
4-biarylyl-1-phenylazetidin-2-ones
|
US7332604B2
(en)
|
2005-09-20 |
2008-02-19 |
Schering Corporation |
1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
|
US8366650B2
(en)
|
2005-10-24 |
2013-02-05 |
Satiogen Pharmaceuticals, Inc. |
Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases
|
ES2374165T3
(es)
|
2005-12-19 |
2012-02-14 |
Glaxosmithkline Llc |
Agonistas del receptor x farnesoide.
|
US20070161578A1
(en)
|
2005-12-21 |
2007-07-12 |
Hwa Joyce J |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
|
AR058985A1
(es)
|
2006-01-13 |
2008-03-05 |
Schering Corp |
Diaril piperidinas como moduladores de cb1.
|
AU2007207706A1
(en)
|
2006-01-18 |
2007-07-26 |
Merck Sharp & Dohme Corp. |
Cannibinoid receptor modulators
|
DE102006009813A1
(de)
|
2006-03-01 |
2007-09-06 |
Bayer Healthcare Ag |
Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
|
WO2007123949A2
(en)
|
2006-04-21 |
2007-11-01 |
Schering Corporation |
Cannabinoid receptor modulators
|
DE102006024024A1
(de)
|
2006-05-23 |
2007-11-29 |
Bayer Healthcare Aktiengesellschaft |
Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
|
DE102006026585A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung
|
DE102006026583A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
|
DE102006042143A1
(de)
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Neue substituierte Bipyridin-Derivate und ihre Verwendung
|
DE102006043519A1
(de)
|
2006-09-12 |
2008-03-27 |
Bayer Healthcare Ag |
4-Phenoxynikotinsäure-Derivate und ihre Verwendung
|
DE102006043520A1
(de)
|
2006-09-12 |
2008-03-27 |
Bayer Healthcare Ag |
2-Phenoxynikotinsäure-Derivate und ihre Verwendung
|
MX2009002918A
(es)
|
2006-09-15 |
2009-03-31 |
Schering Corp |
Derivados azetidinona y sus metodos de uso.
|
MX2009002921A
(es)
|
2006-09-15 |
2009-04-01 |
Schering Corp |
Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
|
EP2066316A1
(en)
|
2006-09-15 |
2009-06-10 |
Schering Corporation |
Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
|
WO2008033456A1
(en)
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
|
CA2663501A1
(en)
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Treating pain, diabetes, and disorders of lipid metabolism
|
US7902157B2
(en)
|
2006-09-15 |
2011-03-08 |
Schering Corporation |
Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
|
MX2009002924A
(es)
|
2006-09-15 |
2009-05-28 |
Schering Corp |
Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
|
WO2008034087A2
(en)
|
2006-09-15 |
2008-03-20 |
Xenoport, Inc. |
Treating schizophrenia with combinations of levodopa and an antipsychotic agent
|
DE102006044696A1
(de)
|
2006-09-22 |
2008-03-27 |
Bayer Healthcare Ag |
3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
|
WO2008039829A2
(en)
|
2006-09-26 |
2008-04-03 |
Ironwood Pharmaceuticals, Inc. |
Diphenylheterocycle cholesterol absorption inhibitors
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
WO2008052044A2
(en)
|
2006-10-26 |
2008-05-02 |
Xenoport, Inc. |
Use of derivatives of propofol for treating diseases associated with oxidative stress
|
DE102006053635B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE102006056740A1
(de)
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
|
DE102006056739A1
(de)
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
|
WO2008088836A2
(en)
|
2007-01-16 |
2008-07-24 |
The Burnham Institute For Medical Research |
Compositions and methods for treatment of colorectal cancer
|
DE102007009494A1
(de)
|
2007-02-27 |
2008-08-28 |
Bayer Healthcare Ag |
Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
|
WO2008124505A2
(en)
|
2007-04-05 |
2008-10-16 |
Ironwood Pharmaceuticals,Inc. |
Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
|
WO2008130616A2
(en)
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
CN102316872B
(zh)
|
2008-11-26 |
2016-12-21 |
萨蒂奥根制药公司 |
治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
|
JO3131B1
(ar)
*
|
2010-04-27 |
2017-09-20 |
Glaxosmithkline Llc |
مركبات كيميائية
|
US20130236541A1
(en)
*
|
2010-11-08 |
2013-09-12 |
Albireo Ab |
Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
|
PL3400944T3
(pl)
*
|
2010-11-08 |
2020-11-16 |
Albireo Ab |
Inhibitory ibat w leczeniu chorób wątroby
|
EP2770990A4
(en)
|
2011-10-28 |
2015-03-11 |
Lumena Pharmaceuticals Inc |
Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease
|
WO2013063512A1
(en)
|
2011-10-28 |
2013-05-02 |
Lumena Pharmaceuticals, Inc |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
RU2015139731A
(ru)
*
|
2013-03-15 |
2017-04-20 |
ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи |
Ингибиторы рециркуляции желчных кислот для лечения первичного склерозирующего холангита и воспалительного заболевания кишечника
|
CA2956833C
(en)
*
|
2014-08-05 |
2022-08-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Synthesis of benzothiazepines
|
MX2017007574A
(es)
|
2014-12-12 |
2018-03-01 |
Kowa Co |
Composicion.
|
KR102116170B1
(ko)
|
2015-06-29 |
2020-05-27 |
야마사 쇼유 가부시키가이샤 |
P1, p4-비스(5''-우리딜)테트라포스페이트 결정의 보관 방법
|
FR3042903B1
(fr)
|
2015-10-21 |
2017-12-08 |
Commissariat Energie Atomique |
Utilisation d'acides hydroxyiminoalcanoiques comme agents anti-nitreux dans des operations de desextraction reductrice du plutonium
|
CA3018132C
(en)
*
|
2016-03-31 |
2024-02-13 |
Genfit |
Use of elafibranor in the treatment of a cholestatic disease
|
EP3475266B1
(en)
*
|
2016-06-27 |
2023-09-06 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
Synthetic methods
|
MX2019012534A
(es)
*
|
2017-04-18 |
2020-08-17 |
Genfit |
Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico.
|
CA3129735A1
(en)
*
|
2019-02-12 |
2020-08-20 |
Mirum Pharmaceuticals, Inc. |
Methods for increasing growth in pediatric subjects having cholestatic liver disease
|